Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder.
Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
To learn more about the company, pipeline and collaboration opportunities, visit us at www.bionomics.com.au.
Location: Australia, South Australia, Adelaide
Employees: 11-50
Total raised: $5M
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | Ambria Cap... | ambriacap.... |
| - | PsyMed Ven... | psymed.ven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.11.2022 | - | $5M | - |
Mentions in press and media 28
| Date | Title | Description | Source |
| 22.02.2024 | Bionomics to Present at the 2024 BIO CEO & Investor Conf... | ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasda... | einpresswi... |
| 05.01.2024 | Bionomics to Present at Biotech Showcase™ 2024 | The Company will provide an update on its leading asset BNC210 and their partnership strategy ADELAI... | einpresswi... |
| 29.09.2023 | Bionomics Announces Positive Topline Results from the Phase ... | ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant re... | en.prnasia... |
| 03.07.2023 | Bionomics Announces Key Leadership Updates to Drive U.S.-Foc... | Alan Fisher appointed Chair of the Board of Directors Tim Cunningham joins as Chief Financial Office... | einpresswi... |
| 30.05.2023 | Bionomics Announces Upcoming Poster Presentation at the Amer... | /EIN News/ -- ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics L... | einpresswi... |
| 19.12.2022 | Bionomics Reports Topline Results in PREVAIL Phase 2 Study o... | BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint Subjects with Co... | einpresswi... |
| 15.12.2022 | Bionomics appoints Spyridon “Spyros” Papapetropoulos as Pres... | Experienced biotech executive to lead the next phase of growth /EIN News/ -- ADELAIDE, Australia, De... | einpresswi... |
| 02.12.2022 | Bionomics Announces Accepted Abstract and Upcoming Poster Pr... | /EIN News/ -- ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX... | einpresswi... |
| 25.10.2022 | Quarterly Activities Report for September 2022 | ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (... | globenewsw... |
| 18.10.2022 | Bionomics Receives R&D Tax Incentive Refund for FY2022 o... | ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (... | globenewsw... |
Show more